Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Study of the Safety and Efficacy of LY3016859 after Multiple Dosing in Diabetic Patients
To investigate the safety and tolerability of multiple IV doses of LY3016859 in DN patients To evaluate the effect of multiple IV dosing of LY3016859 on change from baseline in proteinuria at 16 w...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension
to test the hypothesis that LY518674, administered for 6 weeks to patients with mild essential hypertension, reduces 24-hour mean ambulatory SBP, compared with placebo.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Safety and Efficacy of Exenatide Once Weekly versus Liraglutide in subjects with type 2 diabetes and inadequate glycemic control treated with lifestyle modification and oral antidiabetic medications
The primary objective is to compare the difference in change in HbA1c from baseline to treatment endpoint (26 weeks) between 2 mg exenatide once weekly and 1.8 mg once-daily liraglutide in subjects wi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Eli Lilly and Company
Update Il y a 4 ans
Étude I6F-MC-JJCD : étude de phase 1, évaluant la tolérance du LY3039478, un inhibiteur de Notch, associé à d'autres agents anti-cancéreux, chez des patients ayant un cancer avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, os, organes, etc. Ce sont les cancers les plus fréquents. Il existe plusieurs stades de cancers en fonction de la taille de ...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer
The primary objective of the study is to assess the antitumor activity, as measured by the pathologic complete response (pCR) rate in the breast, of neoadjuvant treatment with two different sequential...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A study of LY2603618 with Pemetrexed and Cisplatin in patients with lung cancer
Primary objective of the Phase 1 part determination of the recommended Phase 2 dose of LY2603618. Primary objective of the Phase 2 part are Determination if the progression-free survival (PFS) time, f...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A study of LY3314814 in early Alzheimer's disease dementia
To evaluate disease modification as outlined in Liu-Seifert (2015). This will be accomplished by testing the three delayed-start hypotheses in both doses of LY3314814 across Study AZES and up to Week...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Study of Nonsteroidal Aromatase Inhibitors Plus LY2835219 or Placebo in Postmenopausal Women With Breast Cancer
The primary objective of Study I3Y-MC-JPBM is to compare treatment with LY2835219 plus NSAI therapy versus placebo plus NSAI therapy with respect to PFS in postmenopausal women with HR+, HER2- locoreg...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Brain Cancer
Phase 1b: To determine the safe and tolerable Phase 2 dose of LY2157299 in combination with radiochemotherapy with temozolomide (TMZ) in patients with glioma. Phase 2a: To confirm the tolerabili...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A 52 Week Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients with Nonradiographic Axial Spondyloarthritis
Compare both ixekizumab regimens (80 mg every 2 weeks [Q2W] or 80 mg every 4 weeks [Q4W]) versus placebo in patients with active nonradiographic axial spondyloarthritis (nonrad-axSpA) at Week 16
Country
None
organs
None
Specialty
None
unknown
More information
Previous
8
9
10
11
12
13
14
15
16
17
Next